Evidence map›Paper›PMID 42026343›Full record

ReviewCellular and molecular life sciences : CMLS2026

Building the bridges: molecular mechanisms of tunneling nanotube formation.

Christel Brou, Chiara Zurzolo

Abstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Emerging Roles of Cytoneme-Mediated Signaling in Cancer.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christel BrouUnité de Trafic Membranaire et Pathogénèse, Département de Biologie Cellulaire et Infection, Institut Pasteur, CNRS UMR3691, Université Paris Cité, Paris, France. christel.brou@pasteur.fr.ORCID http://orcid.org/0000-0003-0229-8202
Chiara ZurzoloUnité de Trafic Membranaire et Pathogénèse, Département de Biologie Cellulaire et Infection, Institut Pasteur, CNRS UMR3691, Université Paris Cité, Paris, France. chiara.zurzolo@pasteur.fr.ORCID http://orcid.org/0000-0001-6048-6602

Funding

Agence Nationale de la Recherche ANR-24-JPW2-0003-02Fondation pour la Recherche Médicale FRM - MND202310017892
6 · The paper itself

Abstract

Tunneling nanotubes (TNTs) are thin, actin-based conduits that provide direct cytoplasmic continuity between cells, enabling the transfer of ions, proteins, organelles, and pathogens. Although discovered nearly two decades ago, the molecular mechanisms that govern TNT biogenesis are only beginning to be resolved. Recent studies have highlighted two main formation modes: filopodia-like protrusion and cell dislodgement. Both likely involve similar molecular steps, but in different sequences. These include regulation by actin dynamics, Rho and Rab GTPases, motor proteins, and membrane-associated adaptors. Environmental stressors such as hypoxia, infection, and inflammation strongly stimulate TNT formation, underscoring their role in adaptation and survival. Understanding the molecular logic of TNT assembly is essential, as these structures influence development, immunity, cancer progression, and neurodegeneration. In this review, we summarize current knowledge of the signaling pathways, cytoskeletal regulators, and membrane remodeling events that drive TNT formation, and discuss outstanding questions.

Indexed as

NanotubesActinsAnimalsCell CommunicationCell MembraneCell Membrane StructuresHumansrho GTP-Binding ProteinsSignal TransductionActinsrho GTP-Binding ProteinsTunneling NanotubesActin regulatorsCell-cell communicationGTPasesTetraspaninsTunneling nanotubes

Identifiers

PMID42026343
PMCPMC13237313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.